If additional procedure codes describing CAR T-cell therapies are approved and finalized, CMS will assign them to the most appropriate MS-DRG.

Market-based MS-DRG policy CMS finalized a dramatic overhaul of MS-DRG rate-setting in the 2021 IPPS final rule, but the 2022 proposed rule seeks to entirely strike out those policies.